Proteome-Based Plasma Markers of Brain Amyloid-β Deposition in Non-Demented Older Individuals
- 7 January 2011
- journal article
- research article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 22 (4) , 1099-1109
Abstract
Blood-based markers reflecting core pathological features of Alzheimer's disease (AD) in pre-symptomatic individuals are likely to accelerate the development of disease-modifying treatments. Our aim was to discover plasma proteins associated with braKeywords
This publication has 50 references indexed in Scilit:
- Extracellular chaperones modulate the effects of Alzheimer’s patient cerebrospinal fluid on Aβ1-42 toxicity and uptakeCell Stress and Chaperones, 2010
- Enhanced clearance of Aβ in brain by sustaining the plasmin proteolysis cascadeProceedings of the National Academy of Sciences, 2008
- Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteinsNature Medicine, 2007
- Amyloid imaging in Alzheimer??s diseaseCurrent Opinion in Neurology, 2007
- Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's diseaseNeuroImage, 2007
- Imaging β-amyloid burden in aging and dementiaNeurology, 2007
- A High-Density Whole-Genome Association Study Reveals That APOE Is the Major Susceptibility Gene for Sporadic Late-Onset Alzheimer's DiseaseThe Journal of Clinical Psychiatry, 2007
- Proteome-based plasma biomarkers for Alzheimer's diseaseBrain, 2006
- Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-BJournal of Cerebral Blood Flow & Metabolism, 2005
- Evolution of the neuropathology of Alzheimer's diseaseActa Neurologica Scandinavica, 1996